Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized B cell malignancy treatment.
• Significant challenges impede CAR-T efficacy in solid tumors, including poor infiltration and immunosuppression.
• Tumor heterogeneity and safety concerns like cytokine release syndrome limit current CAR-T applications.

Purpose of the Study:

• To comprehensively review targeting strategies for enhancing CAR-T therapy in solid tumors.
• To explore advancements in CAR-T cell design, tumor microenvironment modulation, and delivery methods.
• To identify approaches for improving both the safety and efficacy of CAR-T treatments for solid cancers.

Main Methods:

• Review of existing literature on CAR-T cell therapy for solid tumors.
• Analysis of CAR-T cell design principles, including receptor engineering.
• Examination of strategies for overcoming solid tumor barriers and managing toxicities.

Main Results:

• Solid tumors present unique challenges: vascular dysregulation, dense extracellular matrix, and immunosuppressive signals.
• These factors contribute to insufficient CAR-T cell infiltration, rapid dysfunction, and tumor recurrence.
• Safety concerns include cytokine release syndrome, on-target/off-tumor effects, and neurotoxicity.

Conclusions:

• A combinatory approach is essential for successful solid tumor CAR-T therapy.
• Optimized CAR-T cell construction, direct tumor microenvironment manipulation, and suitable delivery strategies are crucial.
• Rational design of these elements will maximize safety and therapeutic efficacy.